76. 下垂体性ゴナドトロピン分泌亢進症 Pituitary gonadotropin secretion hyperthyroidism Clinical trials / Disease details
臨床試験数 : 28 / 薬物数 : 46 - (DrugBank : 14) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 19
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02811471 (ClinicalTrials.gov) | June 2016 | 21/6/2016 | Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty | An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty—Part A and B | Central Precocious Puberty | Drug: Leuprolide | Nemours Children's Clinic | Tolmar Inc. | Recruiting | 2 Years | 9 Years | Both | 5 | Phase 3 | United States |
2 | NCT02452931 (ClinicalTrials.gov) | August 31, 2015 | 5/5/2015 | Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty | An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty | Precocious Puberty, Central | Drug: Leuprolide Acetate 45 mg | Tolmar Inc. | NULL | Completed | 2 Years | 9 Years | All | 64 | Phase 3 | United States;Argentina;Canada;Chile;Mexico;New Zealand |